# Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT

> **NCT06061848** · PHASE2,PHASE3 · RECRUITING · sponsor: **Lars Olaf Cardell** · enrollment: 360 (estimated)

## Conditions studied

- Allergic Rhinitis Due to Grass Pollen

## Interventions

- **DRUG:** SLIT Grazax ALK Nordic 75 000 SQ-T
- **DRUG:** ILIT + Vitamin D
- **DRUG:** ILIT + placebo

## Key facts

- **NCT ID:** NCT06061848
- **Lead sponsor:** Lars Olaf Cardell
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2030-12-28
- **Final completion:** 2031-12-28
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06061848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06061848, "Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06061848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*